Enrolling
:
Myelofibrosis patients with intermediate or high risk by Dynamic International Prognostic Scoring System (DIPSS) in chronic or accelerated phase
Drug
:
Ruxolitinib Phosphate
Company
:
City of Hope Medical Center
Study name
: Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
To learn more click
he
re
.